Cervical Cancer Detection

Globally, cervical cancer is the second-most common cancer in women.¹ Typically, an abnormal Pap test (cytology) or human papillomavirus (HPV) test is followed up with a colposcopy exam and biopsy.²–⁴ Early detection with these tests has reduced cervical cancer mortality.¹ The tests may, however, produce ²–⁴

• False-positive results, leading to additional, unnecessary tests and procedures, increased institutional costs, and patient stress and anxiety
• False-negative results, leading to delays in disease diagnosis

Introducing LuViva® Advanced Cervical Scan

LuViva is a point-of-care device using fluorescence and reflectance spectroscopy to scan the entire uterine cervix for detecting moderate to high-grade cervical dysplasia (cervical intraepithelial neoplasia [CIN] 2 or higher).  LuViva is used before colposcopy or indicated as a follow-up or recall procedure to triage the disease state of women with an abnormal cytology or other risk factors.

LuViva Is Recommended for Women 16 Years of Age or Older Who:

• Have abnormal cytology or positive HPV findings 
• Have other risk factors (eg, previous dysplasia)
• Need additional evaluation before colposcopy or biopsy

Benefits and Risks of LuViva®

• Is noninvasive and fast (real-time results in about a minute)
• May reduce the number of women with normal cervices or low-grade disease having to undergo colposcopy or biopsy⁵ 
• May increase the detection of CIN2+ disease missed by other tests and procedures⁵
• Does not require interpretation by an outside laboratory